Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027391 · ClinicalTrials.gov registry record · NA
Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)
A NA study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT00027391 is a NA study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 160 participants.
The verdict
NCT00027391, a NA study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.
Interventions
- DRUG Albuterol
- DRUG Oxandrolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2001-09 |
| Est. Completion | 2004-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027391
The ClinicalTrials.gov registry entry for NCT00027391 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FDA Office of Orphan Products Development, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol is the first listed.
NCT00027391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027391 about?
NCT00027391 is a clinical study titled "Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)". This is a study to determine whether albuterol or oxandrolone, alone or in combination, are able to increase strength and muscle mass in patients with FSHD. It also will determine if albuterol given in "pulsed" fashion will have more effect than when given continuously.
What is the current status of trial NCT00027391?
This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2001-09. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00027391?
The interventions under investigation include: Albuterol (DRUG), Oxandrolone (DRUG).
Who is sponsoring clinical trial NCT00027391?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.